The great variability in PTH levels of both affected and unaffected patients (i.e., bone marrow fibrosis and/or remodeling) indicates the relationship between SHP and ESA‐resistant anemia is complex and likely unique for each patient. The gene discussed is PTH; the disease is anemia.